The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Effect of Anti-inflammatory Treatment on Depression, Depressive Symptoms, and Adverse Effects: A Systematic Review and Meta-analysis of Randomized Clinical Trials
Open accessAbstract
IMPORTANCE: Several studies have reported antidepressant effects of anti-inflammatory treatment; however, the results have been conflicting and detrimental adverse effects may contraindicate the use of anti-inflammatory agents. OBJECTIVE: To systematically review the antidepressant and possible adverse effects of anti-inflammatory interventions. DATA SOURCES: Trials published prior to December, 31, 2013, were identified searching Cochrane Central Register of Controlled Trials, PubMed, EMBASE, PsychINFO, Clinicaltrials.gov, and relevant review articles. STUDY SELECTION: Randomized placebo-controlled trials assessing the efficacy and adverse effects of pharmacologic anti-inflammatory treatment in adults with depressive symptoms, including those who fulfilled the criteria for depression. DATA EXTRACTION AND SYNTHESIS: Data were extracted by 2 independent reviewers. Pooled standard mean difference (SMD) and odds ratios (ORs) were calculated. MAIN OUTCOMES AND MEASURES: Depression scores after treatment and adverse effects. RESULTS: Ten publications reporting on 14 trials (6262 participants) were included: 10 trials evaluated the use of nonsteroidal anti-inflammatory drugs (NSAIDs) (n=4,258) and 4 investigated cytokine inhibitors (n=2,004). The pooled effect estimate suggested that anti-inflammatory treatment reduced depressive symptoms (SMD, -0.34; 95% CI, -0.57 to -0.11; I2=90%) compared with placebo. This effect was observed in studies including patients with depression (SMD, -0.54; 95% CI, -1.08 to -0.01; I2=68%) and depressive symptoms (SMD, -0.27; 95% CI, -0.53 to -0.01; I2=68%). The heterogeneity of the studies was not explained by differences in inclusion of clinical depression vs depressive symptoms or use of NSAIDs vs cytokine inhibitors. Subanalyses emphasized the antidepressant properties of the selective cyclooxygenase 2 inhibitor celecoxib (SMD, -0.29; 95% CI, -0.49 to -0.08; I2=73%) on remission (OR, 7.89; 95% CI, 2.94 to 21.17; I2=0%) and response (OR, 6.59; 95% CI, 2.24 to 19.42; I2=0%). Among the 6 studies reporting on adverse effects, we found no evidence of an increased number of gastrointestinal or cardiovascular events after 6 weeks or infections after 12 weeks of anti-inflammatory treatment compared with placebo. All trials were associated with a high risk of bias owing to potentially compromised internal validity. CONCLUSIONS AND RELEVANCE: Our analysis suggests that anti-inflammatory treatment, in particular celecoxib, decreases depressive symptoms without increased risks of adverse effects. However, a high risk of bias and high heterogeneity made the mean estimate uncertain. This study supports a proof-of-concept concerning the use of anti-inflammatory treatment in depression. Identification of subgroups that could benefit from such treatment might be warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients who receive cytokine treatments such as IL-2 or IFN γ as part of their treatment for hepatitis or cancer often develop depressive symptoms 82”
From Major depressive disorder (2016) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, Kohler and colleagues found that patients prescribed celecoxib compared to placebo were 7 times more likely to respond to an antidepressant with no increased risks of GI or CV effects (155).”
From Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories (2023) · cites this paper as [155]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“blockade of cytokines, such as TNF, or of inflammatory signalling pathway components, such as cyclooxygenase 2, has been shown to reduce depressive symptoms in patients with medical illnesses, including rheumatoid arthritis, psoriasis and cancer, as well as in patients with major depressive disorder27–29.”
From The role of inflammation in depression: from evolutionary imperative to modern treatment target (2016) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unfortunately, it appears that anti-inflammatory agents may only demonstrate effective antidepressant activity in subgroups of patients who show evidence of increased peripheral inflammation, for example individuals with medical conditions including osteoarthritis and psoriasis that are characterized by increased levels of peripheral inflammation and patients with depression with increased”
From The role of inflammation in depression: from evolutionary imperative to modern treatment target (2016) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“depressive symptoms are more frequent in patients with conditions involving inflammation (e.g., autoimmune diseases) and can be reversed through the use of anti-inflammatory drugs (Kojima et al., 2009; Köhler et al., 2014).”
From The interplay between stress, inflammation, and emotional attention: relevance for depression (2019) · cites this paper as Köhler et al., 2014
In the citing paper
“There is also meta-analytic evidence that anti-inflammatory treatments can be effective means for treating depression (Köhler et al., 2014).”
From The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation. (2018) · cites this paper as Köhler et al., 2014
In the citing paper
“A meta-analysis of nonsteroidal anti-inflammatory drugs and cytokine inhibitors suggests that anti-inflammatory treatment, in particular celecoxib, decreases depressive symptoms in individuals with major depression or with clinically significant depressive symptoms198.”
From Mechanisms and treatment of late-life depression (2019) · cites this paper as [198]
In the citing paper
“There is particular interest in how inflammatory cell types in the brain cause depressive symptoms, as anti-inflammatory treatments reduce depressive symptoms in humans [173] and chronic stress enhances inflammation in animal models [174].”
From The molecular and cellular mechanisms of depression: a focus on reward circuitry (2019) · cites this paper as [173]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560
Assessing Risk of Bias in Included Studies
Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch8 · Cited by 3,396
Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766
Gluud, L. L., Villumsen, J., & Gluud, C. N. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-11-200112040-00010 · Cited by 2,266
The case of the misleading funnel plot
Lau, J., Ioannidis, J. P. A., Terrin, N., Schmid, C. H., & Olkin, I. (2006) · BMJ · doi:10.1136/bmj.333.7568.597 · Cited by 1,766
Flagged first, then by citations
Research works printed but not linked: 2
- [24]24. Raison C, Rutherford RE, Woolwine B, et al. The tumor necrosis factor-alpha antagonist infliximab reduces depressive symptoms in patients with treatment resistant depression and high inflammation. Brain Behav Immun. 2012;26(suppl 1):S49. doi:10.1016/j.bbi.2012.07.200.W. · DOI
- [27]27. Hashemian F, Majd M, Hosseini SM, Sharifi A, Panahi MVS, Bigdeli O. A randomized, double-blind, placebo-controlled trial of celecoxib augmentation of sertraline in the treatment of a drug-naive women with major depression. Klin Psikofarmakol Bul. 2011;21:S183-S184.
Cited by
Sorted by citations
Items 101–200 of 942
Liu, L., Li, J., Su, W., Wang, B., & Jiang, C. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.06.012 · Cited by 155
Wang, Y.-L., Wu, H., Zhang, S., Xiao, H., Yu, J. M., Ma, Y.-Y., Zhang, Y., & Liu, Q. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01468-7 · Cited by 155
Andersson, N. W., Goodwin, R. D., Okkels, N., Gustafsson, L. N., Taha, F., Cole, S. W., & Munk-Jørgensen, P. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyv333 · Cited by 139
Li, W., Ali, T., Zheng, C., Liu, Z., He, K., Shah, F. A., Ren, Q., Rahman, S. U., Li, N., Yu, Z., et al. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02091-5 · Cited by 148
Neuroinflammation and cognition across psychiatric conditions
Fourrier, C., Singhal, G., & Baune, B. T. (2019) · CNS Spectrums · doi:10.1017/s1092852918001499 · Cited by 162
Yin, Y., Ju, T., Zeng, D., Duan, F., Zhu, Y., Liu, J., Li, Y., & Lu, W. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107322 · Cited by 159
Peripheral blood cellular immunophenotype in depression: a systematic review and meta-analysis
Foley, É. M., Parkinson, J. T., Mitchell, R. E., Turner, L., & Khandaker, G. M. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01919-7 · Cited by 138
Horn, S. R., Long, M. M., Nelson, B. W., Allen, N. B., Fisher, P. A., & Byrne, M. L. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.06.016 · Cited by 129
Savitz, J. B., Teague, T. K., Misaki, M., Macaluso, M., Wurfel, B. E., Meyer, M., Drevets, D. A., Yates, W. R., Gleason, O. C., Drevets, W. C., et al. (2018) · Translational Psychiatry · doi:10.1038/s41398-017-0073-7 · Cited by 141
Anti-inflammatory treatments for mood disorders: Systematic review and meta-analysis
Husain, M. I., Strawbridge, R., Stokes, P. R., & Young, A. H. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725711 · Cited by 139
Yang, J., & Jiang, W. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.02.044 · Cited by 142
The renin–angiotensin system: a possible new target for depression
Vian, J., Pereira, C. L., Chavarria, V., Köhler, C. A., Stubbs, B., Quevedo, J., Kim, S., Carvalho, A. F., Berk, M., & Fernandes, B. S. (2017) · BMC Medicine · doi:10.1186/s12916-017-0916-3 · Cited by 136
Can’t or Won’t? Immunometabolic Constraints on Dopaminergic Drive
Treadway, M. T., Cooper, J. A., & Miller, A. H. (2019) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2019.03.003 · Cited by 141
The complex interplay between depression and multimorbidity in late life: risks and pathways
Triolo, F., Harber-Aschan, L., Murri, M. B., Calderón‐Larrañaga, A., Vetrano, D. L., Sjöberg, L., Marengoni, A., & Dekhtyar, S. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111383 · Cited by 136
Inflammatory Depression—Mechanisms and Non-Pharmacological Interventions
Suneson, K., Lindahl, J., Hårsmar, S. C., Söderberg, G., & Lindqvist, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041640 · Cited by 150
The Immune System and the Role of Inflammation in Perinatal Depression
Leff, P., Mancilla‐Herrera, I., Flores‐Ramos, M., Cruz-Fuentes, C. S., Reyes‐Grajeda, J. P., García-Cuétara, M. D. P., Bugnot-Pérez, M. D., & Pulido-Ascencio, D. E. (2016) · Neuroscience Bulletin · doi:10.1007/s12264-016-0048-3 · Cited by 135
Posttraumatic Stress Disorder and Inflammation: Untangling Issues of Bidirectionality
Sumner, J. A., Nishimi, K. M., Koenen, K. C., Roberts, A. L., & Kubzansky, L. D. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.11.005 · Cited by 131
van der Feltz‐Cornelis, C., Allen, S. F., Holt, R. I. G., Roberts, R., Nouwen, A., & Sartorius, N. (2021) · Brain and Behavior · doi:10.1002/brb3.1981 · Cited by 130
Ortega, M. A., Álvarez-Mon, M. Á., Montero, C. G., Fraile‐Μartinez, O., Monserrat, J., Martinez-Rozas, L., Rodríguez–Jiménez, R., Álvarez‐Mon, M., & Lahera, G. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-01964-w · Cited by 137
Inflammation‐driven brain and gut barrier dysfunction in stress and mood disorders
Doney, E., Cadoret, A., Dion‐Albert, L., Lebel, M., & Ménard, C. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15239 · Cited by 134
Mapping inflammation onto mood: inflammatory mediators of anhedonia
Swardfager, W., Rosenblat, J. D., Benlamri, M., & McIntyre, R. S. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.02.017 · Cited by 125
Osimo, E. F., Cardinal, R. N., Jones, P. B., & Khandaker, G. M. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.02.031 · Cited by 124
Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications
Lucido, M. J., Bekhbat, M., Goldsmith, D. R., Treadway, M. T., Haroon, E., Felger, J. C., & Miller, A. H. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000043 · Cited by 133
Major depression and the biological hallmarks of aging
Lorenzo, E. C., Kuchel, G. A., Kuo, C., Moffitt, T. E., & Diniz, B. S. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101805 · Cited by 132
Probiotics for the treatment of depressive symptoms: An anti-inflammatory mechanism?
Park, C., Brietzke, E. M., Rosenblat, J. D., Musial, N., Zuckerman, H., Ragguett, R., Pan, Z., Rong, C., Fus, D., & McIntyre, R. S. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.07.006 · Cited by 131
Khandaker, G. M., Zammit, S., Burgess, S., Lewis, G., & Jones, P. B. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.11.020 · Cited by 118
Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder
Papakostas, G. I., & Ionescu, D. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.92 · Cited by 126
SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders
Amruta, N., Chastain, W. H., Paz, M., Solch-Ottaiano, R. J., Murray-Brown, I. C., Befeler, J. B., Gressett, T. E., Longo, M. T., Engler-Chiurazzi, E. B., & Bix, G. J. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.02.002 · Cited by 123
Depression subtyping based on evolutionary psychiatry: Proximate mechanisms and ultimate functions
Rantala, M. J., Luoto, S., Krams, I. A., & Karlsson, H. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.10.012 · Cited by 125
Fecal transplant prevents gut dysbiosis and anxiety-like behaviour after spinal cord injury in rats
Schmidt, E. K. A., Torres-Espin, A., Raposo, P. J. F., Madsen, K. L., Kigerl, K. A., Popovich, P. G., Fenrich, K. K., & Fouad, K. (2020) · PLoS ONE · doi:10.1371/journal.pone.0226128 · Cited by 119
The role of neuroinflammation and neurovascular dysfunction in major depressive disorder
Jeon, S. W., & Kim, Y. (2018) · Journal of Inflammation Research · doi:10.2147/jir.s141033 · Cited by 123
Dietary inflammatory index and depression: a meta-analysis
Wang, J., Zhou, Y., Chen, K., Jing, Y., He, J., Sun, H., & Hu, X. (2018) · Public Health Nutrition · doi:10.1017/s1368980018002628 · Cited by 122
Circadian depression: A mood disorder phenotype
Carpenter, J. S., Crouse, J. J., Scott, E. M., Naismith, S. L., Wilson, C., Scott, J., Merikangas, K. R., & Hickie, I. B. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.02.045 · Cited by 114
Inflammatory Mediators in Mood Disorders: Therapeutic Opportunities
Pfau, M. L., Ménard, C., & Russo, S. J. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052823 · Cited by 118
Müller, N. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00375 · Cited by 121
Lasselin, J., Lekander, M., Benson, S., Schedlowski, M., & Engler, H. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-00869-2 · Cited by 121
Tong, L., Gong, Y. L., Wang, P., Hu, W., Wang, J., Chen, Z., Zhang, W., & Huang, C. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2270-4 · Cited by 108
Yin, L., Xu, X., Chen, G., Mehta, N. D., Haroon, E., Miller, A. H., Luo, Y., Li, Z., & Felger, J. C. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.05.011 · Cited by 113
Liu, L., Tang, J., Liang, X., Li, Y., Zhu, P., Zhou, M., Lu, Q., Deng, Y., Li, J., Wang, Y., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02464-1 · Cited by 114
The Gut Microbiota Links Dietary Polyphenols With Management of Psychiatric Mood Disorders
Westfall, S., & Pasinetti, G. M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01196 · Cited by 110
Inflammation as a treatment target in mood disorders: review
Jones, B. D. M., Daskalakis, Z. J., Carvalho, A. F., Strawbridge, R., Young, A. H., Mulsant, B. H., & Husain, M. I. (2020) · BJPsych Open · doi:10.1192/bjo.2020.43 · Cited by 106
Physical activity and depression in older adults: the knowns and unknowns
Zhang, S., Xiang, K., Li, S., & Pan, H. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113738 · Cited by 121
Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial
Dean, O. M., Kanchanatawan, B., Ashton, M. M., Mohebbi, M., Ng, C. H., Maes, M. H. J., Berk, L., Sughondhabirom, A., Tangwongchai, S., Singh, A., et al. (2017) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867417709357 · Cited by 106
Stasi, A., Cosola, C., Caggiano, G., Cimmarusti, M. T., Palieri, R., Acquaviva, P. M., Rana, G., & Gesualdo, L. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.925619 · Cited by 115
Immune mechanisms of depression in rheumatoid arthritis
Brock, J., Basu, N., Schlachetzki, J. C. M., Schett, G. A., McInnes, I. B., & Cavanagh, J. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-01037-w · Cited by 108
Miller, A. H., & Raison, C. L. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.22 · Cited by 101
Ormel (2019) · doi:10.1097/yco.0000000000000505 · Cited by 102
Tang, J., Yu, W., Chen, S., Gao, Z., & Xiao, B. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2504-0 · Cited by 102
Medina-Rodriguez, E. M., Lowell, J. A., Worthen, R. J., Syed, S. A., & Beurel, E. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00547 · Cited by 106
Depressive symptoms in inflammatory bowel disease: an extraintestinal manifestation of inflammation?
Moulton, C. D., Pavlidis, P., Norton, C. S., Norton, S., Pariante, C. M., Hayee, B., & Powell, N. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13276 · Cited by 107
Hellmann-Regen, J., Clemens, V., Grözinger, M., Kornhuber, J., Reif, A., Prvulovic, D., Goya-Maldonado, R., Wiltfang, J., Gruber, O., Schüle, C., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.30367 · Cited by 100
Cui, W., Ning, Y., Hong, W., Wang, J., Liu, Z., & Li, M. D. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1306-3 · Cited by 102
The Influence of Antidepressants on the Immune System
Szałach, Ł. P., Lisowska, K. A., & Cubała, W. J. (2019) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-019-00543-8 · Cited by 104
Sun, Y., Wang, D., Salvadore, G., Hsu, B., Curran, M., Casper, C., Vermeulen, J., Kent, J. M., Singh, J., Drevets, W. C., et al. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.06.014 · Cited by 100
Neuroimmune Interface in the Comorbidity between Alcohol Use Disorder and Major Depression
Neupane, S. P. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00655 · Cited by 100
Are medical comorbid conditions of bipolar disorder due to immune dysfunction?
Rosenblat, J. D., & McIntyre, R. S. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12414 · Cited by 97
Bipolar disorder: An evolutionary psychoneuroimmunological approach
Rantala, M. J., Luoto, S., Borráz-León, J. I., & Krams, I. A. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.12.031 · Cited by 104
Euesden, J., Danese, A., Lewis, C. M., & Maughan, B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173015 · Cited by 105
Psychological outcomes following surgical and endoscopic bariatric procedures: A systematic review
Spirou, D., Raman, J., & Smith, E. (2020) · Obesity Reviews · doi:10.1111/obr.12998 · Cited by 104
Andersson, N. W., Gustafsson, L. N., Okkels, N., Taha, F., Cole, S. W., Munk‐Jørgensen, P., & Goodwin, R. D. (2015) · Psychological Medicine · doi:10.1017/s0033291715001488 · Cited by 103
Treatment-Resistant Depression Revisited: A Glimmer of Hope
Halaris, A. E., Sohl, E., & Whitham, E. A. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020155 · Cited by 101
Antidepressants in inflammatory bowel disease
Mikocka-Walus, A., Ford, A. C., & Drossman, D. A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0259-y · Cited by 93
Inflammatory Signaling in Post-Stroke Fatigue and Depression
Wen, H., Weymann, K. B., Wood, L. J., & Wang, Q. M. (2018) · European Neurology · doi:10.1159/000494988 · Cited by 95
Effects of opioid- and non-opioid analgesics on responses to psychosocial stress in humans
Bershad, A. K., Miller, M. A., Norman, G. J., & de Wit, H. (2018) · Hormones and Behavior · doi:10.1016/j.yhbeh.2018.04.009 · Cited by 92
Frank, M. G., Fonken, L. K., Dolzani, S. D., Annis, J. L., Siebler, P. H., Schmidt, D., Watkins, L. R., Maier, S. F., & Lowry, C. A. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.05.020 · Cited by 101
Kim, Y., Amidfar, M., & Won, E. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.06.008 · Cited by 96
Role of Inflammation in Depression and Treatment Implications
Felger, J. C. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_166 · Cited by 94
Hostinar, C. E., Nusslock, R., & Miller, G. E. (2018) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374416.2016.1266647 · Cited by 90
Adjibade, M., Andreeva, V. A., Lemogne, C., Touvier, M., Shivappa, N., Hébert, J. R., Wirth, M. D., Hercberg, S., Galan, P., Julia, C., et al. (2017) · The Journal of Nutrition · doi:10.3945/jn.116.245167 · Cited by 91
Bernardy, N. C., & Friedman, M. J. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0564-2 · Cited by 93
The emerging tale of microglia in psychiatric disorders
Rahimian, R., Wakid, M., O’Leary, L. A., & Mechawar, N. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.09.023 · Cited by 96
Inflammation at the crossroads of COVID-19, cognitive deficits and depression
Silva, N. M. L. E., Barros‐Aragão, F. G. Q., Felice, F. G. D., & Ferreira, S. T. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109023 · Cited by 96
Selective COX-2 Inhibitors: Road from Success to Controversy and the Quest for Repurposing
El‐Malah, A., Gineinah, M. M., Deb, P. K., Khayyat, A. N., Bansal, M., Venugopala, K. N., & Aljahdali, A. S. (2022) · Pharmaceuticals · doi:10.3390/ph15070827 · Cited by 98
Inflammation: A Contributor to Depressive Comorbidity in Inflammatory Skin Disease
Farzanfar, D., Dowlati, Y., French, L. E., Lowes, M. A., & Alavi, A. (2018) · Skin Pharmacology and Physiology · doi:10.1159/000490002 · Cited by 92
Labrenz, F., Wrede, K. H., Forsting, M., Engler, H., Schedlowski, M., Elsenbruch, S., & Benson, S. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.11.010 · Cited by 91
Mohammadi, A. B., Torbati, M., Farajdokht, F., Sadigh‐Eteghad, S., Fazljou, S. M. B., Vatandoust, S. M., Golzari, S. E., & Mahmoudi, J. (2019) · Brain Research · doi:10.1016/j.brainres.2019.03.020 · Cited by 91
Misiak, B., Beszłej, J. A., Kotowicz, K., Szewczuk-Bogusławska, M., Samochowiec, J., Kucharska–Mazur, J., & Frydecka, D. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.04.021 · Cited by 87
Sethi, R., Gómez‐Coronado, N., Walker, A. J., Robertson, O. D., Agustini, B., Berk, M., & Dodd, S. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00605 · Cited by 90
Towards an Effective and Safe Treatment of Inflammatory Pain: A Delphi-Guided Expert Consensus
Varrassi, G., Alon, E., Bagnasco, M., Lanata, L., Mayoral, V., Paladini, A., Pergolizzi, J. V., Perrot, S., Scarpignato, C., & Tölle, T. R. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01053-x · Cited by 93
Wittenberg, G. M., Greene, J., Vértes, P. E., Drevets, W. C., & Bullmore, E. T. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.05.006 · Cited by 83
Aguilar-Valles, A., Haji, N., De Gregorio, D., Matta-Camacho, E., Eslamizade, M. J., Popic, J., Sharma, V., Cao, R., Rummel, C., Tanti, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04883-5 · Cited by 82
GSK3β: a master player in depressive disorder pathogenesis and treatment responsiveness
Duda, P., Hajka, D., Wójcicka, O., Rakus, D., & Gizak, A. (2020) · Cells · doi:10.3390/cells9030727 · Cited by 84
Réus, G. Z., Manosso, L. M., Quevedo, J., & Carvalho, A. F. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105425 · Cited by 94
Serum proteomic profiles of depressive subtypes
Lamers, F., Bot, M., Jansen, R., Chan, M. K., Cooper, J. D., Bahn, S., & Penninx, B. W. J. H. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.115 · Cited by 89
Visceral Inflammation and Immune Activation Stress the Brain
Holzer, P., Farzi, A., Hassan, A. M., Zenz, G., Jačan, A., & Reichmann, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01613 · Cited by 84
Basal and LPS-stimulated inflammatory markers and the course of individual symptoms of depression
van Eeden, W. A., van Hemert, A. M., Carlier, I. V. E., Penninx, B. W. J. H., Lamers, F., Fried, E. I., Schoevers, R. A., & Giltay, E. J. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00920-4 · Cited by 82
Peripheral proinflammatory cytokines in Chinese patients with generalised anxiety disorder
Tang, Z., Ye, G., Chen, X., Pan, M., Fu, J., Fu, T., Liu, Q., Gao, Z., Baldwin, D. S., & Hou, R. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.08.082 · Cited by 83
Effects of inflammation on social processes and implications for health
Moieni, M., & Eisenberger, N. I. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13864 · Cited by 89
Cancer‐related inflammation and depressive symptoms: Systematic review and meta‐analysis
McFarland, D. C., Doherty, M. J., Atkinson, T. M., O’Hanlon, R., BREITBART, W. S., Nelson, C. J., & Miller, A. H. (2022) · Cancer · doi:10.1002/cncr.34193 · Cited by 88
Immune and Neuroprotective Effects of Physical Activity on the Brain in Depression
Phillips, C., & Fahimi, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00498 · Cited by 89
Kaltenboeck, A., & Harmer, C. J. (2018) · Brain and Neuroscience Advances · doi:10.1177/2398212818799269 · Cited by 98
Immunological aspects of the treatment of depression and schizophrenia
Müller, N. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.1/nmueller · Cited by 80
Lim, J., Bang, Y., & Choi, H. J. (2018) · Archives of Pharmacal Research · doi:10.1007/s12272-018-1063-x · Cited by 82
Association between virus exposure and depression in US adults
Gale, S. D., Berrett, A. N., Erickson, L. D., Brown, B. L., & Hedges, D. W. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.12.037 · Cited by 81
In Vivo TSPO Signal and Neuroinflammation in Alzheimer’s Disease
Tournier, B. B., Tsartsalis, S., Ceyzériat, K., Garibotto, V., & Millet, P. (2020) · Cells · doi:10.3390/cells9091941 · Cited by 79
Liu, D., Ray, B., Neavin, D. R., Zhang, J., Athreya, A. P., Biernacka, J. M., Bobo, W. V., Hall‐Flavin, D. K., Skime, M. K., Zhu, H., et al. (2018) · Translational Psychiatry · doi:10.1038/s41398-017-0056-8 · Cited by 80
Is depression the missing link between inflammatory mediators and cancer?
Polityńska, B., Pokorska, O., Wojtukiewicz, A. M., Sawicka, M., Mysliwiec, M., Honn, K. V., Tucker, S. C., & Wojtukiewicz, M. Z. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108293 · Cited by 83
Namba, M. D., Leyrer-Jackson, J. M., Nagy, E. K., Olive, M. F., & Neisewander, J. L. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.650785 · Cited by 76
Psychological co-morbidities in COPD: Targeting systemic inflammation, a benefit for both?
Pelgrim, C. E., Peterson, J. D., Gosker, H. R., Schols, A. M. W. J., van Helvoort, A., Garssen, J., Folkerts, G., & Kraneveld, A. D. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.10.001 · Cited by 85
Bhatnagar, S. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2021.09.005 · Cited by 91
Metadata
- Authors
- Köhler, O., Benros, M. E., Nordentoft, M., Farkouh, M. E., Iyengar, R. L., Mors, O., & Krogh, J.
- Affiliations
- Research Department P, Aarhus University Hospital, Risskov, Denmark2Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus University Hospital, Risskov, Denmark
- University of Copenhagen (DK)
- St. George's University (GD)
- Venue
- JAMA Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2014-12-01
- Volume
- 71
- Issue
- 12
- Pages
- 1381
- ISSN
- 2168-622X (ISSN-L)
- OpenAlex
- W2156150528
- Semantic Scholar
- 04c60d39fcaf20a7ee393c91def9fcd0fd3f10fc
- Cited by
- 941
- References
- 56
- Citations by year
- 2026: 48 · 2025: 62 · 2024: 74 · 2023: 81 · 2022: 88 · 2021: 106 · 2020: 94 · 2019: 85 · 2018: 104 · 2017: 85 · 2016: 70 · 2015: 43 · 2014: 1
- FWCI
- 20.40
- Type
- journal article
- Language
- en
- Open access
- green
- pure.au.dk
- Locations
- JAMA Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Funders
- Lundbeckfonden (R155-2014-1724)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- anti-inflammatory therapy, depression, depressive symptoms, nonsteroidal anti-inflammatory drugs, cytokine inhibitors, celecoxib, COX-2 inhibitors, antidepressant effects, adverse effects, remission, treatment response, adults with depression
- MeSH terms
- Anti-Inflammatory Agents, Depression, Humans, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
